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Treatment Patterns of Multimorbid Patients with
Rheumatoid Arthritis: Results from an International
Cross-sectional Study
Helga Radner, Kazuki Yoshida, Ihsane Hmamouchi, Maxime Dougados, Josef S. Smolen, 
and Daniel H. Solomon
ABSTRACT. Objective. To describe the treatment profile of multimorbid patients with rheumatoid arthritis (RA)
in contrast to patients with RA only.
Methods. COMORA (Comorbidities in Rheumatoid Arthritis) is a cross-sectional, international study
assessing morbidities, outcomes, and treatment of patients with RA. Patients were grouped according
to their multimorbidity profile assessed by a counted multimorbidity index (cMMI). Treatment for
RA was categorized as use of biologic disease-modifying antirheumatic drugs (bDMARD), in
particular tumor necrosis factor inhibitors (TNFi), synthetic DMARD (sDMARD) use only,
nonsteroidal antiinflammatory drug (NSAID) use, and corticosteroid use. Logistic regression models
were performed to determine the OR of bDMARD, TNFi, sDMARD, NSAID, or corticosteroid use
based on a patient’s cMMI and global region after adjusting for age, disease activity, disease duration,
educational level, and previous DMARD therapy.
Results. Out of 3920 patients, 32.7% received bDMARD; 59.9% sDMARD only, 51.1% used
concomitant NSAID, and 54.8% used corticosteroid. Regional differences were observed with the
most frequent use of bDMARD in the United States (46.5%) and lowest in North Africa (9%). After
adjusting for confounders in logistic regression, the OR for bDMARD use was reduced for each
additional morbidity (OR 0.89, 95% CI 0.83–0.96). Similar results were found for TNFi (OR 0.91,
95% CI 0.84–0.99), whereas the OR for use of sDMARD was increased (1.13, 95% CI 1.05–1.22).
No significant change of OR was found for NSAID or corticosteroid use.
Conclusion. In this study, the odds of bDMARD use decreases 11% for each additional chronic
morbid condition after adjustment for regional differences, disease activity, and other covariates. 
(J Rheumatol First Release June 1 2015; doi:10.3899/jrheum.141534)
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Because inflammatory rheumatic conditions are mostly
systemic diseases, a high prevalence of coexisting disorders
can be observed. The average patient with rheumatoid
arthritis (RA) has 1.6 additional conditions, increasing with
age, disease duration, and/or disease activity1,2. While these
are mostly considered as comorbidities in the setting of an
index disease, in chronic morbid patients, multimorbidity
might be a more useful concept. In contrast to the concept of
comorbidity, it uses a patient-centered approach, rather than
focusing on a single index condition3. Multimorbidity takes
into account all potential interactions of coexisting diseases
and its effect on patients’ overall well-being.
It is known from previous studies that multimorbid
patients with RA are potentially undertreated for their
concomitant diseases4, which reduces important outcomes of
these ailments. However, because of multimorbidity, one may
also observe less intensive treatment of RA than indicated5.
This might be partly a consequence of older age and general
tendency to undertreat elderly patients6,7. It might also be
because of concerns of increased adverse events or inter-
action with other medications in the presence of multimor-
bidity8. This can cause higher activity of RA and therefore
impairs all its major outcomes, such as physical function,
quality of life, work productivity, or even mortality. Research
has shown that there is no difference in treatment response
in elderly patients with RA (65 yrs and older) compared with
younger patients9,10. Nevertheless, coexisting diseases have
been identified as negative predictors for response to
therapy11,12; therefore, multimorbid patients with RA might
require more intensive treatment to achieve treatment targets.
Treatment recommendations such as treat-to-target aim for
optimal therapeutic approaches to achieve remission, con -
sidering the presence of coexisting morbidities13.
Previous studies have shown a negative association of
biological disease-modifying antirheumatic drug (bDMARD)
initiation and presence of comorbidity in patients with RA5,
investigating only small cohorts without incorporating the
concept of multimorbidity. To our knowledge, this is the first
large international study to assess the cross-sectional treat -
ment profile of multimorbid patients with RA from 17
different countries worldwide. Our aim was to assess the
effect of multimorbidity on treatment status, accounting for
factors that affect treatment decisions, including disease
activity and regional differences.
MATERIALS AND METHODS
Study cohort. Comorbidities in Rheumatoid Arthritis (COMORA) is an inter-
national, cross-sectional, observational study of more than 3900 patients
with RA recruited in 17 countries worldwide between 2011 and 201214. The
National Principal Investigators were instructed to recruit rheumatologists
representative of their respective countries to conduct the study. Consecutive
patients visiting participating rheumatologists were included if they were 18
years or older and fulfilled the 1987 American College of Rheumatology
(ACR) classification criteria for RA15. Ethical approval was obtained by all
local institutional review boards or ethics committees. 
Assessment of multimorbidity. In COMORA, variables of disease activity
and severity, as well as information on specific morbidities, were collected
by each participating rheumatologist using charts, medical records, and/or
patient interview (for details see original COMORA paper14). Based on these
data, we calculated the counted multimorbidity index (cMMI), an index
based on the effect of multimorbidity on health-related quality of life
(HRQOL) that originally included 40 different morbid conditions16. cMMI
was developed and validated in a large RA cohort, in which it was shown to
perform better in explaining the effect of comorbidity on HRQOL than the
commonly used Charlson Comorbidity Index. Out of 40 conditions, 12
conditions were reported in COMORA (hypertension, obesity, depression,
cancer, asthma, coronary heart disease, viral hepatitis, chronic obstructive
pulmonary disease, diabetes mellitus, chronic kidney disease, diverticulitis,
and stroke), and cMMI was calculated by enumerating the particular number
of morbidities for each patient. As shown in a previous work, a short form
of the index including only 12 conditions served as a valid alternative16.
Patients were divided into 5 groups according to cMMI: RA only (cMMI =
1) and multimorbid RA with 1 (cMMI = 2), 2 (cMMI = 3), 3 (cMMI = 4),
and 4 or more (cMMI ≥ 5) additional chronic morbid conditions.
Outcome of interest. To assess treatment patterns, we used information on
current and previous RA therapy collected in COMORA: DMARD [type,
starting and/or ending date, and reason for discontinuation of all synthetic
DMARD (sDMARD) and bDMARD ever used], nonsteroidal antiinflam-
matory drug (NSAID; current intake collected according to the Assessment
of Spondyloarthritis international Society recommendations, including name
and dosage)17, and corticosteroids (intake in mg/day as well as the estimated
total intake of corticosteroids from the beginning of the disease). We cate -
gorized information on RA treatment: current use of sDMARD only
(yes/no), current use of bDMARD in general (yes/no), current use of tumor
necrosis factor inhibitor in particular (TNFi; yes/no), current corticosteroid
intake (yes/no), current NSAID intake (yes/no), and number of previous
DMARD (synthetic and/or biologic).
Statistical analyses. We categorized patients according to cMMI into 5
groups and compared patients’ characteristics across the groups. In the
primary analyses, we assessed whether certain treatment patterns may be
associated with the multimorbidity status. In unadjusted analyses, we inves-
tigated differences of current and previous treatment status between groups
of patients with different cMMI using the chi-square test and ANOVA testing
for linear trend. We also looked for regional differences and split the cohort
into region of origin: (1) Europe: Austria, France, Germany, Hungary, Italy,
the Netherlands, Spain, and UK; (2) United States; (3) Asia: Japan, Korea,
and Taiwan; (4) Latin America: Argentina, Uruguay, and Venezuela; and (5)
North Africa: Egypt and Morocco.
In adjusted analyses, we included factors associated with RA treatment,
such as disease activity by Clinical Disease Activity Index (CDAI), disease
duration, age, sex, education level, serological status, number of previous
DMARD, and region. We decided a priori on clinically meaningful variables
to be included in logistic regression analyses. In 4 different models we calcu-
lated the odds of current treatment with bDMARD, TNFi, sDMARD,
NSAID, or corticosteroids for different status of multimorbidity according
to cMMI. Using the Box-Tidwell test, we could confirm that including
cMMI as a continuous variable in regression models did not violate
assumption of linearity. In secondary analyses, we calculated OR of
bDMARD and TNFi use for specific morbid conditions.
All statistical analyses were carried out using IBM SPSS Statistics
version 21.
RESULTS
The study sample consisted of 3920 patients, and 2563
(65.4%) were multimorbid with more than 1 chronic
condition in addition to RA. The median cMMI was 2
(25th/75th percentile 1/3, range 1–10). Patients’ character-
istics of the total study sample as well as subgroups of
patients according to their cMMI are shown in Table 1, with
significant differences between RA only and multimorbid
patients with RA. In general, multimorbid patients were older
and experienced higher disease activity measured by CDAI
and Disease Activity Score at 28 joints, worse physical
function evaluated by Health Assessment Questionnaire
(HAQ) or modified HAQ, and longer disease duration
compared with patients with RA only. This decrease of
physical function and quality of life with increasing cMMI,
and the increase in disease duration, age, and disease activity
with increasing cMMI follows a linear trend (Table 1). The
prevalence of different morbid conditions is shown in
Supplementary Table 1, available online at jrheum.org.
Unadjusted analyses. Overall, 92.6% of the patients were
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receiving DMARD therapy, 32.7% received a bDMARD,
59.9% were receiving sDMARD only, 51.1% had concomi -
tant NSAID use, and 54.8% corticosteroid intake. In
unadjusted analyses, there were no differences in frequency
of current DMARD use, TNFi use, or corticosteroid use
between RA only and multimorbid patients with RA (p >
0.05). In contrast to adjusted analyses, without adjusting for
important confounders, higher rates of bDMARD use in
multimorbid patients with RA were observed. The frequency
of current NSAID use was significantly lower in multimorbid
patients (Supplementary Table 2, available online at jrheum.org).
To account for regional differences, data from different
countries were grouped according to their geographical
region. In general, the United States had the highest median
cMMI of 3 (range 1–10) compared with all other regions
(Europe median 2, range 1–9; Asia median 2, range 1–6;
Latin America median 2, range 1–7; North Africa median 2,
range 1–6; Kruskal-Wallis test p < 0.01).
Looking at overall regional differences of current
treatment use, we found significantly less bDMARD and
TNFi treatment use in the North African (bDMARD 9%,
TNFi 1.1%) and Asian (bDMARD 16%, TNFi 12.8%)
subgroups of patients compared with all other regional
subgroups (p < 0.01). The United States had the highest
bDMARD use (46.5%) and the lowest corticosteroid use
(27.9%; Figure 1). Regional differences across patients with
different level of cMMI are displayed in Supplementary
Figure 1, available online at jrheum.org.
Adjusted analyses. In logistic regression analyses, we
examined the use of (1) bDMARD, (2) TNFi, (3) sDMARD,
(4) NSAID, and (5) corticosteroids as the outcome in relation
to cMMI; models were adjusted for disease activity by CDAI,
disease duration, age, sex, educational level, number of
previous DMARD, serological status, and geographic region.
Nagelkerke R2 was 0.26 for the model predicting current
bDMARD use, 0.17 for current TNFi use, 0.25 for sDMARD
use only, 0.14 for current NSAID use, and 0.14 for current
corticosteroid use. In the final model, the OR of current
bDMARD use for cMMI was 0.89 (95% CI 0.83–0.96, p =
0.05), which means that for each point increase of cMMI, the
odds of current bDMARD use decreases by 11%. Similar
results were found for TNFi use: OR cMMI = 0.91 (95% CI
0.84–0.99, p = 0.04; Table 2). Further, Asia or North Africa
had a significantly lower OR of receiving either bDMARD
or TNFi compared with Europe. The OR for sDMARD use
only was 1.13 (95% CI 1.05–1.22, p = 0.003). The OR of
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Table 1. Patients’ characteristics for the total study sample (first column) as well as subgroups of patients according to their level of the cMMI. Values are mean
(SD) or % unless otherwise specified.
Characteristics Total Study Subgroups of Patients according to Multimorbidity Index, cMMI
Sample, n = 3920 RA Only, cMMI = 2,  cMMI = 3,  cMMI = 4,  cMMI ≥ 5, p
n = 1357 n = 1047 n = 725 n = 430 n = 361 
(34.6%) (26.7%) (18.5%) (11.0%) (9.2%)
Age, yrs 56.3 (13.0) 51.0 (13.3) 58.4 (12) 58.8 (12.9) 59.1 (11.2) 61.3 (10.9) < 0.01*
Female 81.7 82.2 81.9 81.5 79.8 81.7 0.86^
Disease duration, 
yrs 9.6 (8.7) 8.4 (7.5) 10.2 (9.1) 10.4 (9.3) 10.1 (8.9) 10.2 (9.5) < 0.01*
Seropositive, RF, 
and/or ACPA 82.2 84.6 81.7 80.1 79.9 81.5 0.06^
SJC28 2.7 (4.0) 3.0 (4.1) 2.5 (3.6) 2.7 (3.9) 2.8 (4.2) 2.6 (4.1) 0.23*
TJC28 4.0 (5.4) 3.8 (5.4) 3.6 (4.8) 4.3 (5.5) 4.7 (6.0) 4.7 (5.7) < 0.01*
ESR 26.8 (22.7) 26.1 (22.5) 25.1 (22.5) 27.8 (22) 28.3 (23.2) 30.8 (24.3) < 0.01*
DAS28 3.7 (1.6) 3.7 (1.6) 3.6 (1.5) 3.8 (1.5) 3.9 (1.6) 4.0 (1.5) < 0.01*
CDAI 13.7 (11.6) 13.5 (11.9) 12.8 (10.7) 13.9 (11.6) 14.9 (13.0) 15.3 (11.7) < 0.01*
HAQ 1.04 (0.7) 0.93 (0.6) 0.98 (0.6) 1.11 (0.7) 1.16 (0.7) 1.27 (0.7) < 0.01*
mHAQ 0.51 (0.6) 0.42 (0.5) 0.46 (0.5) 0.57 (0.6) 0.61 (0.6) 0.7 (0.6) < 0.01*
PtGA 3.9 (2.6) 3.7 (2.5) 3.7 (2.5) 4.0 (2.6) 4.1 (2.7) 4.3 (2.6) < 0.01*
EGA 3.0 (2.2) 2.9 (2.2) 2.8 (2.1) 2.9 (2.3) 3.2 (2.4) 3.3 (2.2) < 0.01*
EQ-5D 0.68 (0.3) 0.72 (0.3) 0.70 (0.2) 0.65 (0.3) 0.63 (0.3) 0.60 (0.3) < 0.01*
No. DMARD 
taken overall 2.8 (1.7) 2.6 (1.6) 2.8 (1.7) 2.7 (1.8) 2.9 (1.8) 2.9 (1.9) 0.014*
Smoking current 13.2 12.1 13.5 13.2 14.3 14.9 0.58^
Married 69.7 71.5 69.6 69.8 68.0 64.7 0.15^
Education highest 
level university 25.0 28.1 24.2 21.1 20.7 23.6 < 0.01^
Erosive disease 53.7 52.3 54.9 55.6 52.2 54.2% 0.55^
* Analyses of variance testing for linear trend. ^ Chi-square test for trend. cMMI: counted multimorbidity index; RA: rheumatoid arthritis; RF: rheumatoid
factor; ACPA: anticitrullinated protein antibodies; SJC28: swollen joint count at 28 joints; TJC28: tender joint count at 28 joints; ESR: erythrocyte sedimentation
rate; DAS28: Disease Activity Score at 28 joints; CDAI: Clinical Disease Activity Index; HAQ: Health Assessment Questionnaire; mHAQ: modified HAQ;
PtGA: patient’s global assessment; EGA: evaluator global assessment; DMARD: disease-modifying antirheumatic drugs.
current NSAID or corticosteroid use was not significant for
cMMI.
In secondary analyses, we calculated OR for each morbid
condition, showing significant lower OR of bDMARD use
and TNFi use for cancer (OR 0.67, 95% CI 0.49–0.90;
Supplementary Table 3, available online at jrheum.org). OR
was also lower for other conditions, though not statistically
significant. To ensure that our primary results were not driven
by the presence of cancer, we repeated the logistic regression
models explained above, excluding patients with cancer and
found very similar OR (results not shown).
DISCUSSION
We were interested in the treatment profile of multimorbid
patients with RA compared with patients with RA only. In a
large international cohort, we found that the OR of being
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Table 2. Multivariate logistic regression models predicting the probability of current bDMARD use, TNFi use, sDMARD use only, NSAID use, and corticosteroid
use (steroids). Variables included in the model are the cMMI, age, disease duration, number of previous DMARD, disease activity, education level, and region.
For bDMARD and TNFi, the OR is decreasing with increasing value of the cMMI. Values are OR (95% CI).
Adjusted Model bDMARD TNFi sDMARD NSAID Steroids
cMMI 0.89 (0.83–0.96)* 0.91 (0.84–0.99)* 1.13 (1.05–1.22)* 1.06 (0.99–1.14) 1.05 (0.98–1.13)
Age, yrs 0.99 (0.98–1.00)* 0.99 (0.98–1.00)* 1.01 (1.00–1.02) 0.98 (0.97–0.99)* 1.00 (0.99–1.01)
Disease duration, yrs 1.02 (1.00–1.03)* 1.03 (1.01–1.04)* 0.99 (0.98–1.00) 1.01 (1.00–1.02)* 1.00 (0.99–1.01)
No. previous DMARD 1.27 (1.18–1.37)* 0.94 (0.87–1.02) 0.71 (0.65–0.77)* 1.05 (0.98–1.13) 1.21 (1.12–1.30)*
CDAI 0.98 (0.97–0.99)* 0.96 (0.95–0.97)* 1.00 (0.99–1.01) 1.03 (1.02–1.04)* 1.04 (1.03–1.06)*
Education level, university 1.32 (1.02–1.72)* 1.22 (0.91–1.62) 0.64 (0.50–0.84)* 0.97 (0.76–1.24) 1.15 (0.90–1.47)
Europe, reference REF REF REF REF REF
USA 2.25 (1.47–3.46)* 2.02 (1.33–3.06)* 0.32 (0.19–0.52)* 1.06 (0.71–1.57) 0.43 (0.28–0.65)*
Asia 0.26 (0.20–0.35)* 0.42 (0.31–0.58)* 4.00 (3.04–5.25)* 4.48 (3.4–5.91)* 2.56 (1.96–3.35)*
Latin America 1.00 (0.68–1.47) 1.09 (0.72–1.64) 1.18 (0.80–1.75) 1.90 (1.28–2.80)* 1.00 (0.68–1.47)
North Africa 0.11 (0.07–0.17)* 0.05 (0.02–0.13)* 4.41 (3.05–6.36)* 0.62 (0.44–0.87)* 2.00 (1.40–2.87)*
* p < 0.05. DMARD: disease-modifying antirheumatic drugs; bDMARD: biological DMARD; TNFi: tumor necrosis factor inhibitors; sDMARD: synthetic
DMARD; NSAID: nonsteroidal antiinflammatory drugs; cMMI: counted multimorbidity index; CDAI: Clinical Disease Activity Index; REF: reference.
Figure 1. Regional differences of current treatment status including bDMARD, TNFi, sDMARD, NSAID, and corticosteroid (steroids) use.
DMARD: disease-modifying antirheumatic drugs; bDMARD: biological DMARD; TNFi: tumor necrosis factor inhibitor; sDMARD:
synthetic DMARD; NSAID: nonsteroidal antiinflammatory drug.
treated with a bDMARD in general or a TNFi in particular
was lower for multimorbid patients, with a decrease of
roughly 10% per additional morbid condition. This would
mean that patients with a high number of chronic conditions
in addition to RA were less likely to receive a biological
agent, even if it might be necessary because of high RA
disease activity despite synthetic DMARD treatment. Further,
the OR for sDMARD use only increased, probably reflecting
rheumatologists’ greater comfort of using these agents in
patients with a greater multimorbidity burden.
Even though these are cross-sectional analyses, findings are
consistent with previous studies, showing that the initiation of
biological therapy is less likely in patients with RA with
concomitant diseases5. This might be a consequence of older
age and a general tendency to undertreat elderly patients6,7, but
also attributable to concerns of increased adverse events or
polypharmacy8. Current treatment recommendations of the
ACR, the European League Against Rheumatism, or the treat-
to-target task force13,18,19 aim for optimal therapeutic
outcomes, considering concomitant diseases.
Optimal treatment of RA affects the patient’s overall
condition. Concomitant chronic conditions, such as cardio-
vascular disease, are closely linked to the inflammatory
process of RA20,21,22. Intensive treatment that controls RA
activity might improve insulin resistance and cardiovascular
risk, which has been shown for TNFi23,24,25. Withholding
bDMARD in multimorbid patients with RA might worsen the
patient’s RA and other chronic conditions present. It might
increase the incidence of concomitant diseases and worsen
overall outcomes.
On the contrary, treatment with more potent agents such
as bDMARD might increase the risk of serious adverse
events, such as infections or malignancies26,27. Several drugs
are contraindicated in patients with specific morbidities (for
example, abatacept in chronic obstructive pulmonary
disease28,29, TNFi in recent-onset cancer30, etc.) that makes
treatment of multimorbid patients with RA more challenging.
After adjusting for important covariates, we confirmed the
negative association of multimorbidity and bDMARD use
reported in literature. We used a described multimorbidity
index that allows for easy assessment of the patient’s overall
disease status. Moreover, in contrast to previous studies, we
used a large international RA cohort of more than 3900
patients from various regions and with varying disease
activity and disease duration. COMORA included patients
from 17 different nations, allowing us to also compare current
treatment across different global regions. We could observe
regional differences of bDMARD and TNFi use, with highest
overall use in the United States and lowest use in North
Africa. Because TNFi are one of the most commonly used
bDMARD in the treatment of RA, and contraindications
differ from those of other biological agents, we specifically
addressed the association of TNFi use and multimorbidity in
separate analyses.
We found significantly lower odds of bDMARD/TNFi use
if cancer was present. For other morbidities (such as stroke,
chronic kidney disease, etc.), we found similar results, though
not statistically significant; this might be because of the low
prevalence of the diseases in our cohort or the fact that some
conditions (such as hypertension or obesity) were regarded
as rather mild and presumably would not influence treatment
choices when treating patients with RA.
Several limitations need to be addressed. COMORA is a
cross-sectional study. Therefore, it is not possible to inves-
tigate causality; mitigated treatment might be because of
multimorbidity or vice versa. Second, as mentioned in the
original COMORA paper14, the study population might not
be fully representative for all patients with RA in the partici -
pating countries. Despite the efforts to recruit rheumatolo-
gists working in different practice settings to enroll patients,
the study does not include patients with RA from general
practices not seeing a rheumatologist. This might reflect a
selection bias as patients seeing a rheumatologist might
experience more severe disease activity. Further, even
though COMORA has no specific inclusion or exclusion
criteria except for having RA, there might be a selection
bias, recruiting only those patients doing well or being more
compliant. There might be some inter-country variability,
especially for bDMARD therapy, explained by different
country-specific treatment guidelines, number of approved
bDMARD, reimbursement policies, and more31. Across the
5 regions, there could be cultural differences as well as
differences in affordability, accessibility, and acceptability
of DMARD therapy. Nevertheless, the large sample of
patients enrolled from each country allows accounting for
some of the limitations. Finally, even after adjusting for all
important covariates, our models explained only up to 25%
of the reason for using bDMARD. Several factors that might
affect the prescription of bDMARD, such as patient prefer-
ences, insurance status, or patient income, were not
evaluated in COMORA and therefore not included in our
model.
We were able to show that multimorbid patients with RA
were less likely to receive bDMARD or TNFi therapy
compared with patients with RA only; there were also
regional differences in bDMARD use. Even though these are
cross-sectional findings with several caveats, we should be
aware of potential undertreatment of patients with 1 or more
additional chronic conditions than RA. Longitudinal studies
are needed to investigate whether this undertreatment affects
longterm outcomes such as disease activity, radiographic
progression, physical function, organ damage, or mortality.
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